Clinical Trials

The CBTC has opened a clinical trial in canine meningioma. Funding for the clinical trial has been generously provided by the American Kennel Club-Canine Health Foundation. We are evaluating Procaspase-3 Activator (PAC-1) in combination with Hydroxyurea for the treatment of canine meningioma. The trial is being led by Dr. Timothy Fan, and is open for recruitment at University of Pennsylvania and Virginia-Maryland Medical College. Dogs enrolled on study will also come to the National Cancer Institute to receive advanced imaging as part of the study.

Additional trial concepts are currently in development.

Sponsor: AKC-Canine Health Foundation

Study Numbers: 6-8 dogs anticipated

Participating Sites:

Eligibility Requirements:

  • Prior MRI with a diagnosis of meningioma
  • Informed owner consent
  • No prior radiation or chemotherapy

MRI Consensus Document

The CBTC will be publishing a MRI Consensus document later this year in an effort to develop  consensus recommendations for a standardized brain tumor imaging protocol for clinical trials using the canine model, such that: 1) multi-institutional studies can be performed with minimal inter-institutional variation, and 2) imaging protocols are consistent with human consensus recommendations to permit reliable translation to human clinical trials.

This effort is led by Dr. Rebecca Packer.